Advertisement
News
Advertisement

Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium

Tue, 10/19/2010 - 10:33am
Bio-Medicine.Org

COLUMBIA, Md., Oct. 19 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that two abstracts on the ThermoDox® High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2nd International Symposium.  The abstracts provide strong proof of concept, as well as the rationale and support for future clinical studies, which will combine ThermoDox with MR-guided HIFU for cancer indications.  The symposium is being held October 17-20, 2010 at the Westfields Marriott in Dulles, VA .  

The first abstract, titled "MR-guided High Intensity Focused Ultrasound Enhances Targeted Drug Delivery of Low Temperature Sensitive Liposomes in a Rabbit Vx2 Tumor Model," is authored by Ashish Ranjan from the National Institutes of Health, Bethesda, MD, USA.  The second abstract, titled "Thermally-mediated Localized Drug Release Using MRI-Controlled Focused Ultrasound Hyperthermia," is authored by Robert Staruch from Sunnybrook Health Sciences Centre and University of Toronto, Canada.  Additional co-authors from the two studies are from Duke University, University of Helsinki, Finland, and Philips Healthcare.  The abstracts are available on the company's website site at www.celsion.com.  

"We are delighted to expand our HIFU program to leading oncology research centers in the US, Canada and Europe," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We hope to make a seamless transition to clinical studies in these and additional countries based on the preclinical data that has been developed through our joint research agreement with Philips Healthcare.  Celsion and Philips are now well positioned to submit our clinical program for FDA review. Assuming we have agreement, we expect

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading